🔗 Visit the ClinicalTrials.gov page for NCT00440726
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. | Blood | 2012 | 1.33 |
| 2 | Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. | Pediatr Blood Cancer | 2010 | 1.15 |
| 3 | Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. | Haematologica | 2012 | 0.90 |
| 4 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |